Association of hypertensive disorders of pregnancy with future cardiovascular disease
File(s)rayes_2023_oi_230005_1675954466.25182.pdf (1002.13 KB)
Published version
Author(s)
Type
Journal Article
Abstract
Importance Hypertensive disorders in pregnancy (HDPs) are major causes of maternal and fetal morbidity and are observationally associated with future maternal risk of cardiovascular disease. However, observational results may be subject to residual confounding and bias.
Objective To investigate the association of HDPs with multiple cardiovascular diseases.
Design, Setting, and Participants A genome-wide genetic association study using mendelian randomization (MR) was performed from February 16 to March 4, 2022. Primary analysis was conducted using inverse-variance-weighted MR. Mediation analyses were performed using a multivariable MR framework. All studies included patients predominantly of European ancestry. Female-specific summary-level data from FinnGen (sixth release).
Exposures Uncorrelated (r2<0.001) single-nucleotide variants (SNVs) were selected as instrumental variants from the FinnGen consortium summary statistics for exposures of any HDP, gestational hypertension, and preeclampsia or eclampsia.
Main Outcomes and Measures Genetic association estimates for outcomes were extracted from genome-wide association studies of 122 733 cases for coronary artery disease, 34 217 cases for ischemic stroke, 47 309 cases for heart failure, and 60 620 cases for atrial fibrillation.
Results Genetically predicted HDPs were associated with a higher risk of coronary artery disease (odds ratio [OR], 1.24; 95% CI, 1.08-1.43; P = .002); this association was evident for both gestational hypertension (OR, 1.08; 95% CI, 1.00-1.17; P = .04) and preeclampsia/eclampsia (OR, 1.06; 95% CI, 1.01-1.12; P = .03). Genetically predicted HDPs were also associated with a higher risk of ischemic stroke (OR, 1.27; 95% CI, 1.12-1.44; P = 2.87 × 10−4). Mediation analysis revealed a partial attenuation of the effect of HDPs on coronary artery disease after adjustment for systolic blood pressure (total effect OR, 1.24; direct effect OR, 1.10; 95% CI, 1.02-1.08; P = .02) and type 2 diabetes (total effect OR, 1.24; direct effect OR, 1.16; 95% CI, 1.04-1.29; P = .008). No associations were noted between genetically predicted HDPs and heart failure (OR, 0.97; 95% CI, 0.76-1.23; P = .79) or atrial fibrillation (OR, 1.11; 95% CI, 0.65-1.88; P = .71).
Conclusions and Relevance The findings of this study provide genetic evidence supporting an association between HDPs and higher risk of coronary artery disease and stroke, which is only partially mediated by cardiometabolic factors. This supports classification of HDPs as risk factors for cardiovascular disease.
Objective To investigate the association of HDPs with multiple cardiovascular diseases.
Design, Setting, and Participants A genome-wide genetic association study using mendelian randomization (MR) was performed from February 16 to March 4, 2022. Primary analysis was conducted using inverse-variance-weighted MR. Mediation analyses were performed using a multivariable MR framework. All studies included patients predominantly of European ancestry. Female-specific summary-level data from FinnGen (sixth release).
Exposures Uncorrelated (r2<0.001) single-nucleotide variants (SNVs) were selected as instrumental variants from the FinnGen consortium summary statistics for exposures of any HDP, gestational hypertension, and preeclampsia or eclampsia.
Main Outcomes and Measures Genetic association estimates for outcomes were extracted from genome-wide association studies of 122 733 cases for coronary artery disease, 34 217 cases for ischemic stroke, 47 309 cases for heart failure, and 60 620 cases for atrial fibrillation.
Results Genetically predicted HDPs were associated with a higher risk of coronary artery disease (odds ratio [OR], 1.24; 95% CI, 1.08-1.43; P = .002); this association was evident for both gestational hypertension (OR, 1.08; 95% CI, 1.00-1.17; P = .04) and preeclampsia/eclampsia (OR, 1.06; 95% CI, 1.01-1.12; P = .03). Genetically predicted HDPs were also associated with a higher risk of ischemic stroke (OR, 1.27; 95% CI, 1.12-1.44; P = 2.87 × 10−4). Mediation analysis revealed a partial attenuation of the effect of HDPs on coronary artery disease after adjustment for systolic blood pressure (total effect OR, 1.24; direct effect OR, 1.10; 95% CI, 1.02-1.08; P = .02) and type 2 diabetes (total effect OR, 1.24; direct effect OR, 1.16; 95% CI, 1.04-1.29; P = .008). No associations were noted between genetically predicted HDPs and heart failure (OR, 0.97; 95% CI, 0.76-1.23; P = .79) or atrial fibrillation (OR, 1.11; 95% CI, 0.65-1.88; P = .71).
Conclusions and Relevance The findings of this study provide genetic evidence supporting an association between HDPs and higher risk of coronary artery disease and stroke, which is only partially mediated by cardiometabolic factors. This supports classification of HDPs as risk factors for cardiovascular disease.
Date Issued
2023-02
Date Acceptance
2023-01-03
Citation
Jama Network Open, 2023, 6 (2), pp.1-13
ISSN
2574-3805
Publisher
American Medical Association
Start Page
1
End Page
13
Journal / Book Title
Jama Network Open
Volume
6
Issue
2
Copyright Statement
This is an open access article distributed under the terms of the CC-BY License. © 2023 Rayes B
et al. JAMA Network Open.
et al. JAMA Network Open.
License URL
Sponsor
British Heart Foundation
British Heart Foundation
Identifier
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801582
Grant Number
RG/16/3/32175
RG/F/22/110078
Subjects
Female
Humans
Pregnancy
Atrial Fibrillation
Cardiovascular Diseases
Coronary Artery Disease
Diabetes Mellitus, Type 2
Eclampsia
Genome-Wide Association Study
Heart Failure
Hypertension, Pregnancy-Induced
Ischemic Stroke
Pre-Eclampsia
Mendelian Randomization Analysis
Humans
Hypertension, Pregnancy-Induced
Eclampsia
Pre-Eclampsia
Cardiovascular Diseases
Atrial Fibrillation
Diabetes Mellitus, Type 2
Pregnancy
Female
Coronary Artery Disease
Heart Failure
Genome-Wide Association Study
Mendelian Randomization Analysis
Ischemic Stroke
Publication Status
Published
Article Number
e230034
Date Publish Online
2023-02-17